Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose<sup>131</sup>I therapy

宋娟娟; 刘延晴; 林岩松

doi:10.19401/j.cnki.1007-3639.2019.03.008

您当前的位置：

首页 >

文章列表页 >

Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy

更新时间：2026-01-27

- Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy
- China Oncology Vol. 29, Issue 3, Pages: 207-211(2019)
- 作者机构：
  
  1. 中国医学科学院北京协和医学院北京协和医院核医学科,北京,100730
  2. 北京大学国际医院核医学科,北京,102206
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.03.008
  CLC： R736.1
- Published Online：26 April 2019，
  
  Published：26 April 2019
- 稿件说明：
移动端阅览
宋娟娟，刘延晴，林岩松. 中低危分化型甲状腺癌低剂量

宋娟娟, 刘延晴, 林岩松. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy[J]. China Oncology, 2019, 29(3): 207-211.
宋娟娟，刘延晴，林岩松. 中低危分化型甲状腺癌低剂量 DOI： 10.19401/j.cnki.1007-3639.2019.03.008.

宋娟娟, 刘延晴, 林岩松. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy[J]. China Oncology, 2019, 29(3): 207-211. DOI： 10.19401/j.cnki.1007-3639.2019.03.008.

摘要

背景与目的：2015版美国甲状腺协会（American Thyroid Association，ATA）指南首次提出治疗反应评估体系（response-to-therapy assessment system，RTAS）。该研究根据此评估体系，探讨低剂量（1 110 MBq）

131

I在中低危分化型甲状腺癌（differentiated thyroid carcinoma，DTC）清甲治疗后短期内不同转归的影响因素。方法：回顾性分析2015年1月—2017年1月166例中低危DTC患者资料，男性50例，女性116例，平均年龄（39.61±10.23）岁。首次清甲剂量为1 110MBq，取得清甲前及清甲后6~12个月刺激性甲状腺球蛋白（stimulated thyroglobulin，sTg）及诊断性全身显像（diagnosticwhole body scan，Dx-WBS），根据结果分为最佳治疗反应（excellent response，ER）组与非最佳反应（non-excellent response，NER）组。采用两样本t检验、Mann-Whitney U秩和检验及χ

检验进行组间临床病理资料比较，采用Logistic回归分析影响清甲疗效的因素，采用受试者工作特征（receiver operating characteristic，ROC）曲线确定最佳界值。结果：ER组127例，NER组39例，ER率为76.5%（127/166）。治疗后短期随访ER组清甲治疗前sTg（preablative sTg，ps-Tg）明显低于NER组［1.5（0.04-30.57）ng/mL vs 17.6（0.04-21.52）ng/mL；U=2 479，P0.05］，且性别、年龄差异有统计学意义，男性及年龄稍小者更易出现NER。多因素分析显示，ps-Tg水平、肿瘤大小、淋巴结转移数目、性别、年龄及多灶性均为影响清甲疗效的相关因素（OR：0.361~2.875）。ROC曲线分析显示，ps-Tg最佳临界值为2.0 ng/mL。结论：ps-Tg水平较低、病灶较小、淋巴结转移数目较少、男性、年龄较小及单灶患者清甲治疗后短期内更易达到ER；且以ps-Tg值2.0 ng/mL为最佳临界点，对预测治疗后短期临床转归有较高的灵敏度和特异度。

Abstract

Background and purpose: The concept of response-to-therapy assessment system (RTAS) was first proposed in the 2015 American Thyroid Association (ATA) guidelines. This study aimed to investigate the different short-term outcomes of thyroid ablation with low-dose (1 110 MBq)

131

I for low-to-intermediate-risk thyroid cancer based on this system

and its probable influence factors. Methods: A total of 166 patients with differentiated thyroid carcinoma (DTC) ［50 males

116 females; average age: (39.61±10.23) years］ undergoing first thyroid ablation with 1 100 MBq

131

I from January 2015 to January 2017 were retrospectively observed. All patients underwent diagnostic whole body scan (Dx-WBS)

and the stimulated thyroglobulin (sTg) was measured before ablation and 6-12 months after ablation respectively. According to above results

patients were divided into excellent response (ER) group and non-excellent response (NER) group. Clinical and pathological characteristics of 2 groups were compared using two-sample t test

Mann-Whitney U test and χ

test. Logistic regression was used to identify the influence factors for efficacy of

131

I ablation

and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. Results: There were 127 patients in ER group and 39 patients in NER group. The successful ablation rate was 76.5% (127/166). Patients in ER group showed lower preablative sTg (ps-Tg) compared with patients in NER group. The ps-Tg levels were 1.5 (0.04-30.57) ng/mL and 17.6 (0.04- 21.52) ng/mL respectively (U=2 479

P0.05). Male and patient with younger age were more prevalent in NER group (P0.05). Logistic regression showed that ps-Tg

tumor size

the number of metastatic lymph nodes

gender

age and multifocality were independent predictors for efficacy of

131

I ablation (OR: 0.361-2.875). The optimal cut-off value of ps-Tg identified by ROC curve analysis was 2.0 ng/mL. Conclusion: The pati

ents with lower ps-Tg

smaller diameter of tumor

fewer lymph node metastases

male

younger age and single lesion are more likely to have ER within a short period following thyroid ablation. Ps-Tg of 2.0 ng/mL is identified as cut-off value for predicting the short-term therapeutic response

which has preferable sensitivity and specificity.

关键词

Keywords

references

查看原文

Views

2027

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical outcome of ¹³¹I therapy in differentiated thyroid cancer patients with suspicious high thyroglobulin concentration

The role of diagnostic whole body scan in decision-making of ¹³¹I treatment for differentiated thyroid cancer

Clinical outcome after¹³¹I treatment in differentiated thyroid cancer with negative stimulated thyroglobulin and lymph node metastasis

Correlation between minimal extrathyroid invasion and recurrence in differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in external beam radiotherapy (EBRT) for differentiated thyroid cancer

Related Author

Yansong LIN

Xiaona JIN

Yingqiang ZHANG

Zheng LI

Zhuanzhuan MU

Wenting GUO

Yansong LIN

Bing YAN

Related Institution

Department of Radionuclide Treatment Center, Beijing Nuclear Industry Hospital

Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine

Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Nuclear Medicine, Beijing Hope Medcare

AI问答

⁰

Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose131I therapy

DOI：10.19401/j.cnki.1007-3639.2019.03.008

摘要

Abstract

关键词

Keywords

references

Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy